Compare XRPN & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XRPN | CRVS |
|---|---|---|
| Founded | 2024 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 704.6M | 843.7M |
| IPO Year | 2026 | 2016 |
| Metric | XRPN | CRVS |
|---|---|---|
| Price | $8.84 | $10.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $31.50 |
| AVG Volume (30 Days) | 669.2K | ★ 927.7K |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 48.04 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $72.74 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.39 | $6.39 |
| 52 Week High | $48.00 | $26.95 |
| Indicator | XRPN | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 38.53 | 50.16 |
| Support Level | N/A | $9.40 |
| Resistance Level | $10.47 | $10.81 |
| Average True Range (ATR) | 1.20 | 0.67 |
| MACD | -0.59 | 0.20 |
| Stochastic Oscillator | 19.58 | 52.73 |
Evernorth Holdings Incis a purpose-built investment vehicle focused on holding XRP through the public equity markets. It provides institutional investors with exposure to XRP through a publicly traded vehicle. The company manages its XRP assets through activities that may include the acquisition of XRP, portfolio management, yield generation strategies, and geographic expansion. The company also focuses on the XRP Ledger, a public blockchain designed to facilitate financial transactions.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.